Müller K D, Grebe S F, Bock F L, Müller H, Fängewisch G L
Bereich Nuklearmedizin, Kerckhoff-Klinik der MPG, Bad Nauheim.
Nuklearmedizin. 1994 Jun;33(3):87-92.
The purpose of this study was to determine differences in 131I biokinetics after oral or intravenous treatment of hyperthyroidism (0.81 GBq) or differentiated thyroid cancer (1.85 GBq) following thyroidectomy. 20 patients with differentiated carcinoma and 20 patients with hyperthyroidism were studied. In each group 10 patients were treated perorally and 10 patients intravenously. The integrated whole-body activities during therapy were significantly lower, by an average 23% (cancer) and 45% (hyperthyroidism) than after oral application. It is most likely that these differences between oral and intravenous application are due to the higher serum activity after intravenous therapy. It is concluded that a higher activity dose of 131I must be given orally to achieve the same target dose as after intravenous application.
本研究的目的是确定甲状腺切除术后口服或静脉注射治疗甲状腺功能亢进（0.81GBq）或分化型甲状腺癌（1.85GBq）后131I生物动力学的差异。研究了20例分化型癌患者和20例甲状腺功能亢进患者。每组10例患者口服治疗，10例患者静脉注射治疗。治疗期间的全身积分活度显著低于口服给药后，平均低23%（癌症）和45%（甲状腺功能亢进）。口服和静脉注射应用之间的这些差异很可能是由于静脉治疗后血清活度较高。得出的结论是，必须口服更高活度剂量的131I才能达到与静脉注射应用后相同的靶剂量。
